pharmaceutical investing Fortress Biotech Reports Fourth Quarter and Full-Year 2017 Financial Results
pharmaceutical investing Fortress Biotech Announces Aevitas Therapeutics Enters Sponsored Research Agreement with the University of Massachusetts Medical School
Jubilant Biosys Enters into Exclusive out-Licensing Agreement with Checkpoint Therapeutics for Novel BET Inhibitors
Fortress Biotech Presents Positive Data from the Phase 1/2 Study of CNDO-109-Activated Allogeneic Natural Killer Cells in Acute Myeloid Leukemia at the Innate Killer Summit 2016
Mustang Bio Announces Oral Presentation of Initial Clinical Data for MB-101 (IL13Ra2-specific CAR T cells) by City of Hope Investigators at the American Society of Gene and Cell Therapy 19th Annual Meeting
Element79 Gold Corp Announces Corporate Update and Strategic Leadership Changes With Focus On Accelerating Nevada Asset Development
